Abstract Number: 152 • 2017 Pediatric Rheumatology Symposium
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is…Abstract Number: 89 • 2017 Pediatric Rheumatology Symposium
Abatacept as Adjunct Therapy for the Calcinosis of Juvenile Dermatomyositis: A Single-Center Experience
Background/Purpose: Juvenile dermatomyositis (JDMS) is an autoimmune inflammatory myopathy which primarily manifests with skin, muscle, and blood vessel involvement. Dystrophic calcification or calcinosis has been…Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting
Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab
Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…Abstract Number: 2000 • 2016 ACR/ARHP Annual Meeting
Incidence of Cancer in Patients with Rheumatoid Arthritis and a History of Cancer Treated with Rituximab or Abatacept
Background/Purpose: Patients with a history of cancer were excluded from pivotal clinical trials evaluating biologics. Therefore, only registries can inform us on the incidence of…Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
Background/Purpose: Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…Abstract Number: 268 • 2016 ACR/ARHP Annual Meeting
Effect of Abatacept Treatment on T Cells in Muscle Tissue and Peripheral Blood in Polymyositis and Dermatomyositis Patients
Background/Purpose: Abatacept (CTLA4-Ig), a blocking agent for T cell co-stimulation, has been proven beneficial in several autoimmune diseases. The aim of the study was to…Abstract Number: 2494 • 2016 ACR/ARHP Annual Meeting
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
Background/Purpose: Abatacept is an effective biologic agent indicated for the treatment of RA.1 Recent studies have indicated that obesity and being overweight could reduce the…Abstract Number: 389 • 2016 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Background/Purpose: Abatacept is a widely approved and used biologic in children with juvenile idiopathic arthritis (JIA). The purpose of this study was to describe the…Abstract Number: 2527 • 2016 ACR/ARHP Annual Meeting
Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors
DRUG RETENTION OF BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS: THE ROLE OF BASELINE CHARACTERISTICS AND IMPACT OF TIME-VARYING FACTORS D.S. Courvoisier1, D. Alpizar-Rodriguez1, JE. Gottenberg2, F. Iannone4,…Abstract Number: 402 • 2016 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Background/Purpose: The comparative risk of infection with newer biologic agents, such as abatacept (ABA), in the treatment of juvenile idiopathic arthritis (JIA) has not been…Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting
Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?
Background/Purpose: Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…Abstract Number: 2553 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database
Background/Purpose: Women are affected by RA 3–4 times more often than men. RA treatment choice during pregnancy can be a challenge for women to minimize…Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…Abstract Number: 2583 • 2016 ACR/ARHP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »